Gunjan L. Shah, MD
Tufts Medical Center Oncology
Boston Massachusetts, USA
Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database
Medicare coverage for Auto HSCT for MM began in 10/2000. By 2009, MM was the leading indication for this treatment (CIBMTR, 2011). The survival benefit and cost implications of the rise in Auto HSCT are not well described in this population. Using SEER-Medicare data, we explored these implications for MM patients (pts) age 66+ by comparing them with pts not undergoing Auto HSCT.
Advertisement
Visit our website at: http://www.myeloma.org